VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Elderly mRCC patients should not be excluded from targeted therapy option

Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.

1 Jul 2014

Partial nephrectomy predicts survival among metastatic RCC patients

Cytoreductive nephrectomy predicts improved survival among patients with metastatic renal cell carcinoma and synchronous metastases who have received first-line treatment with sunitinib, indicate study findings.

1 Jul 2014

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

30 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

Study sheds light on new potential treatment for heat stroke

Scientists in Taiwan have found that intravenous injections of stem cells derived from human exfoliated deciduous tooth pulp (SHED) have a protective effect against brain damage from heat stroke in mice. Their finding was safe and effective and so may be a candidate for successfully treating human patients by preventing the neurological damage caused by heat stroke.

6 Jun 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

The Obama administration calls it an adjustment, Republicans call it a bailout and insurance companies call it the one thing that might keep them from raising rates and angering policyholders.

28 May 2014

New drug approach for safer clean-up of deformed blood vessels in eye

A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto.

12 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

New research suggests that Kindlin-3 regulates 2 major hallmarks of breast cancer

A protein believed to be limited to the hematopoietic system, called Kindlin-3, has been identified as a major player in both the formation and spread of breast cancer to other organs.

2 May 2014

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration.

1 May 2014

Ranibizumab trial gets promising results for CNV

Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial.

1 May 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.

22 Apr 2014

Scientists examine Gpr109a receptor to find potential treatment for diabetic retinopathy

Like a daily pill to lower cholesterol can reduce heart attack and stroke risk, an easy-to-use agent that reduces eye inflammation could help save the vision of diabetics, scientists say.

22 Apr 2014